Glenmark Pharmaceuticals Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Glenmark Pharmaceuticals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹2,452

Market cap₹68.8K Cr

P/E22.0

Published8 Sept 2026

What the Q1 FY27 call signalled

1 of 4 strong

RevenueRank 3

MarginRank 3

CapexYes

FundraiseNo

Not discussed on this call: order book.

The short version

India business expected to grow consistently at 12%-15% annually, driven by strong brands and new product launches like Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, and BRUKINSA. Glenmark expects sustained growth, particularly driven by India with 12%-15% consistent growth projected (Page 9, 11, 12). - Upcoming product launches in India (Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, BRUKINSA) and respiratory launches in the U.S.

From Glenmark Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 8 Sept 2026.

Revenue & Sales Performance

Rank 3

India business expected to grow consistently at 12%-15% annually, driven by strong brands and new product launches like Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, and BRUKINSA.
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong.
U.S. business growth supported by upcoming respiratory launches in H2 FY27, with Monroe differentiated injectables kicking in next year.
Europe expected to grow at high single digits this year, moving towards double-digit growth with increasing focus on branded products (targeting ~60% branded revenue in 5 years).
New oncology specialty portfolio and innovative products (e.g., ISB 2001, IGI pipeline assets 2301 and 2302) to contribute to medium- and long-term growth.
Margin outlook remains stable at 21%-22% despite cost pressures, supported by improved product and geographical mix.
Continued investment in field force expansions in India and emerging markets to support launches and growth.

Profitability & Margins

Glenmark expects sustained growth, particularly driven by India with 12%-15% consistent growth projected (Page 9, 11, 12).
Upcoming product launches in India (Aumolertinib, Trastuzumab Rezetecan, TEVIMBRA, BRUKINSA) and respiratory launches in the U.S. (second half FY27) will fuel future earnings growth (Pages 9, 10, 11, 12).
Europe is targeted to return to double-digit growth from next year, led by branded respiratory and dermatology products (Page 7).
Margin guidance remains stable at around 21%-22%, despite cost pressures from raw materials and logistics, due to improved product and geographic mix (Pages 6, 8, 12).
Working capital and balance sheet remain strong with gross debt at zero, supporting growth investments (Page 12).
R&D investment will continue (~7-8% of revenue), especially behind advanced pipeline assets like ISB 2301, indicating future earnings potential from innovation (Page 7).
Overall, management confident in executing growth plans to achieve enhanced profitability in FY28 and beyond (Pages 9, 11, 12).

See what Glenmark Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Glenmark is making strategic investments to strengthen oncology commercial capabilities, especially in emerging markets, to prepare for launches of Aumolertinib, Trastu Reze, and envafolimab.
These investments support a projected INR500-600 million revenue over 5-6 years from these oncology brands.
The same infrastructure will be leveraged for launching ISB 2001 in the future, indicating ongoing capital commitment to innovative oncology assets.
R&D investment remains significant, with a quarterly spend of around INR289 crores and an annual guidance of 7-8% of revenue.
The company is preparing for clinical advancement and commercialization of IGI pipeline assets like ISB 2301, which may require incremental future investment post clinical proof of concept.
Working capital initiatives and debt management (maintaining gross debt zero) support financial flexibility for these strategic investments.

Fundraising & Capital Structure

Glenmark Pharmaceuticals currently maintains a gross debt zero position as confirmed by CFO Anurag Mantri.
The company intends to continue maintaining this zero gross debt stance going forward.
Cash positions are stable around INR 800-900 crores to support operations and growth.
No mention of any immediate or planned fundraising through either debt or equity during the call.
Emphasis is on working capital optimization, cost management, and internal cash flows to fund operations and R&D.
The company appears comfortably funded for its near to medium term clinical and commercial activities without the need for external fundraising.

See what Glenmark Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from Glenmark Pharmaceuticals Limited's Q1 FY27 earnings call does not explicitly mention the current or expected order book or pending orders. However, the following related points provide insight into business outlook and growth: - Glenmark reported broad-based growth across all regions with consolidated revenues up 23.1% year-on-year. - Strong momentum in India with 18.1% growth in formulation business and significant market share gains. - Several key launches in oncology, respiratory, and chronic care areas are underway or planned. - Preparations and product approvals expected in the U.S. respiratory segment in H2 FY27 to drive growth. - Robust pipeline including partnered oncology assets and innovative respiratory products advancing. - The company maintains a gross debt zero position and focuses on working capital optimization, indicating stable order fulfillment capacity. No specific quantitative data on order book or pending orders was disclosed.

How does Glenmark Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisGlenmark Pharmaceuticals Ltd

Rev 3Mar 3

See where Glenmark Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹3.9K Cr, net profit ₹403 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Glenmark Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…
Ind-Swift Labs. (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Glenmark Pharmaceuticals Ltd Q1 FY27 results?

What is Glenmark Pharmaceuticals Ltd share price analysis?

Glenmark Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.0 with a market cap of ₹68,784 Cr. Investors should review the full earnings analysis for detailed insights.

Is Glenmark Pharmaceuticals Ltd planning capital expenditure?

Glenmark is making strategic investments to strengthen oncology commercial capabilities, especially in emerging markets, to prepare for launches of Aumolertinib, Trastu Reze, and envafolimab.

Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.